PraxisUnico
PraxisUnico is a UK-based, educational not-for-profit organisation 'set up to support innovation and commercialisation of public sector and charity research for social and economic impact.'
Technology transfer net
Ascenion works with colleagues and peers around the world to develop professional standards, initiate new technology…
The current COVID-19 pandemic has drastically made us aware of how inadequate the present precautions are against infections transmitted by droplets and aerosols. Else Kröner-Fresenius-Stiftung wants to encourage the development of more efficient protective strategies, materials and measures, and is awarding up to 1 million euros for projects…
On 26-28 April 2021, decision makers from biotech, pharma and finance will meet digitally to learn about emerging life-science trends and initiate partnerships with academic inventors, entrepreneurs and technology transfer professionals from all over Europe.
This year, 16 technology transfer organizations from seven nations have brought together…
HDP-101 is the most advanced candidate derived from the company’s unique ATAC (Antibody Targeted Amanitin Conjugates) platform. It consists of highly specific anti-BCMA antibodies coupled with amanitin, a highly effective toxin that is found in certain mushrooms including the death cap. The conjugates combine the antibodies’ specificity with the…
The new Innovative Training Network (ITN) ‘Advanced Machine Learning for Innovative Drug Discovery’ (AIDD) receives EUR 3.93 million from the European Union within the framework of the Marie-Skłodowska-Curie actions. The consortium and associated partners from around the world will offer comprehensive, structured training to 16 PhD students…
Together, the partners will evaluate the application of a new approach for generating human pluripotent stem cell-derived macrophages for the treatment of acute and chronic bacterial pulmonary infections. The technology’s inventors include MHH scientists Prof. Dr Nico Lachmann, Dr Mania Ackermann and Dr Robert Zweigerdt.
Ascenion has been working…
The same high standard in a fresh format: BioVaria is switching completely over to digital this year. From the 26 to 28 April 2021, European scientists, clinicians and entrepreneurs will come together with international business developers and investors in the life-science sector to discuss the latest trends and developments in innovation and…
Ascenion is delighted to receive the funding, which will facilitate the creation of new opportunities to efficiently support GO-Bio initial applications and projects. The grant will initially run for a period of four years.
The focus of Ascenion’s funded concept 'Life Science Digital Hub' is to advance the level of development of early…
We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive collaboration over the past special year.
Instead of sending Christmas cards, we have decided to support a charity. We will be making a donation to 'Ärzte der Welt e. V.', an association that offers…
Following the recent publication of impressive preclinical data on its MKK4 inhibitor in acute liver disease, HepaRegeniX now reports positive results in nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC). In relevant in vivo models, MKK4 inhibition was not only safe and well tolerated but even showed marked growth…
The funding provided by the non-profit organization CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) enables the partners to further advance their promising approach towards application. It is based on groundbreaking research by Mark Brönstrup’s team at the Helmholtz Centre for Infection Research (HZI). Their goal is…
The compound is an antisense oligonucleotide inhibiting certain micro-RNAs in heart tissue that regulate the pathological growth of heart muscle cells. In the trial, CDR132L met all endpoints and showed excellent tolerability and safety. The infusion was very well tolerated by all patients, and no safety signals or unexpected adverse events were…
The ITN, led by Hannover Medical School (MHH), pursues an inter-sectoral approach to develop novel strategies for treating spinal muscular atrophy (SMA), a rare neurodegenerative disease with a significant unmet medical need.
Ascenion will provide training to raise the researchers’ awareness for the commercial and societal impact of their work.…
